Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has commenced in the United States District Court for the District of Maryland against Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (Nasdaq:OSIR) on behalf all persons or entities who purchased Osiris securities between May 12, 2014 and November 20, 2015, inclusive (the “Class Period”).
Shareholders who incurred losses on shares purchased within the Class Period are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
If you purchased the shares of Osiris Therapeutics, Inc., you may, no later than January 22, 2016, request that the Court appoint you lead plaintiff of the proposed class.
On November 16, 2015, the Company surprised investors by disclosing that it had “determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014.”
Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Osiris Investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
